Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Hi-Tech Pharmacal Receives Tentative Approval for Calcipotriene Topical Solution
April 11th, 2007
Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced that the US Food and Drug Administration (FDA) has granted tentative approval to the Company's Abbreviated New Drug Application (ANDA) for Calcipotriene topical solution, 0.005%. Hi-Tech's Calcipotriene topical solution is the generic equivalent of Warner Chilcott's Dovonex(R) topical solution, 0.005% indicated for the treatment of psoriasis of the scalp, which had sales of $13 million in 2006 based on IMS sales data. Hi-Tech does not plan to market its generic version of Dovonex(R) topical solution prior to expiration of patent 4,866,048, which is due to expire on December 29, 2007. Hi-Tech is a specialty...
Source: Medical Patent Law Weekly (2007-04-11)
|
